HIDRADENITIS SUPPURATIVA (HS)

This study tests whether the experimental drug NAV-240 can reduce painful skin bumps and draining tunnels in people with moderate-to-severe hidradenitis suppurativa (HS). About 150 adults who have had HS for at least 6 months and have not responded well to antibiotics will receiv…

This study gives people with hidradenitis suppurativa (HS) who already benefited from povorcitinib in earlier trials the chance to keep taking it. Researchers will track side effects and check how well the drug controls skin abscesses and inflammation over time. About 600 adults …

This program provides access to secukinumab (AIN457) for people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or use available therapies. Doctors must request access on behalf of their p…

This study tests a new medicine called BFB759 for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 210 adults will receive either the drug or a placebo for up to 40 weeks to see if it reduces abscesses and inflamed bumps. The goal is t…

This study tests a new drug called CIT-013 for people with hidradenitis suppurativa (HS), a painful skin condition. About 96 adults with moderate to severe HS will receive either a low or high dose of CIT-013 or a placebo every two weeks for 12 weeks. The main goal is to see if C…

This study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses and scarring. Participants receive either the drug or a placebo to see if it reduces skin bumps and inflamma…

This study tests a new drug called povorcitinib in 40 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and tunnels. The goal is to see if the drug is safe and can reduce symptoms over 54 weeks. Participants …

This study tests if a medicated foam called roflumilast can help people with hidradenitis suppurativa, a skin condition that causes painful lumps. About 20 adults with mild to moderate disease will use the foam daily for 16 weeks. The goal is to see if it reduces the number of in…

This study tests whether high-dose radiotherapy can provide lasting relief for people with moderate to severe hidradenitis suppurativa (HS) that hasn't responded to other treatments. Ten adults with HS in both armpits will receive radiation to one armpit while the other continues…

This study tests a new drug called tibulizumab for adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. About 225 people will receive either the drug or a placebo for 16 weeks, then all can get the drug for another 16 weeks. The goal is to se…

This study tests whether a new wound dressing called Pelashield PainGuard helps people heal better after surgery for hidradenitis suppurativa (HS) compared to the current standard dressing, Restrata. Pelashield contains silver to fight bacteria and lidocaine to reduce pain. Ten a…

This study is a survey of 77 adults in Saudi Arabia with moderate to severe hidradenitis suppurativa (HS) who are starting a new medication called Cosentyx (secukinumab). The goal is to see how satisfied patients are with the treatment after 24 weeks, focusing on convenience, sid…

This study tests whether a special laser (1726-nm) can safely reduce painful lumps and abscesses caused by hidradenitis suppurativa (HS), a long-term skin condition. Thirty adults with mild-to-moderate HS will have one side of their body treated with the laser and the other side …

This study watches people who already got a gene-modified Treg treatment for rheumatoid arthritis or hidradenitis suppurativa. Researchers want to see if any delayed side effects show up over time. About 36 participants will be followed to track safety and how long the modified c…